Compounds > edotreotide
Page last updated: 2024-09-04

edotreotide and lutetium lu 177 dotatate

edotreotide has been researched along with lutetium lu 177 dotatate in 11 studies

Compound Research Comparison

Studies
(edotreotide)		Trials
(edotreotide)		Recent Studies (post-2010)
(edotreotide)		Studies
(lutetium lu 177 dotatate)		Trials
(lutetium lu 177 dotatate)		Recent Studies (post-2010) (lutetium lu 177 dotatate)
206348635641301

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (18.18)29.6817
2010's9 (81.82)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bernard, BF; Breeman, WA; de Jong, M; Krenning, EP; Valkema, R1
Arveschoug, AK; Hjorthaug, K; Højgaard, L; Mortensen, J; Oturai, PS; Rehling, M1
Buck, AK; Flentje, M; Hänscheid, H; Kreissl, M; Löhr, M; Samnick, S; Sweeney, RA; Verburg, FA1
Baum, RP; Kulkarni, HR; Müller, D; Prasad, V; Schuchardt, C; Zachert, C1
Baum, RP; Kulkarni, HR; Schuchardt, C1
Baum, RP; Kulkarni, HR; Prasad, V; Schuchardt, C1
Bergsma, H; de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; Peeters, RP; Teunissen, JJ; van Vliet, EI1
Cacciari, G; Campana, D; Capurso, G; Delle Fave, G; Falconi, M; Nori, F; Panzuto, F; Partelli, S; Tamburrino, D; Tomassetti, P1
Amato, E; Bodei, L; Botta, F; Cremonesi, M; Ferrari, ME; Fioroni, F; Grassi, E; Guerriero, F; Iori, M; Pacilio, M; Paganelli, G; Pedroli, G; Sarnelli, A; Strigari, L; Versari, A1
Baio, SM; Bodei, L; Colandrea, M; Fazio, N; Galetta, D; Gilardi, L; Grana, CM; Mariniello, A; Paganelli, G; Papi, S; Tinelli, C; Valmadre, G1
Bartenstein, P; Baum, RP; Bengel, FM; Biersack, HJ; Dunkelmann, S; Ezziddin, S; Gratz, KF; Haug, A; Hörsch, D; Krause, BJ; Miederer, M; Pöpperl, G; Schreckenberger, M1

Trials

1 trial(s) available for edotreotide and lutetium lu 177 dotatate

ArticleYear
Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors.
    BioMed research international, 2013, Volume: 2013

    Topics: Aged; Aged, 80 and over; Calibration; Cohort Studies; Humans; Kidney; Kinetics; Middle Aged; Octreotide; Organometallic Compounds; Radiometry; Receptors, Peptide; Risk Factors; Time Factors; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed

2013

Other Studies

10 other study(ies) available for edotreotide and lutetium lu 177 dotatate

ArticleYear
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46 Suppl 1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Humans; Lutetium; Male; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Somatostatin; Survival Analysis; Treatment Outcome; Yttrium

2005
[Peptide receptor radionuclide therapy of neuroendocrine tumors].
    Ugeskrift for laeger, 2009, Mar-23, Volume: 171, Issue:13

    Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Yttrium Radioisotopes

2009
PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma.
    European journal of nuclear medicine and molecular imaging, 2012, Volume: 39, Issue:8

    Topics: Adult; Aged; Biological Transport; Female; Gallium Radioisotopes; Humans; Male; Meningioma; Middle Aged; Molecular Targeted Therapy; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Receptors, Somatostatin; Somatostatin

2012
The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194

    Topics: Adult; Aged; Female; Humans; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Whole-Body Counting

2013
Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194

    Topics: Aged; Female; Humans; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin

2013
Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194

    Topics: Blood Cells; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiation Dosage; Radiopharmaceuticals; Receptors, Somatostatin; Spleen

2013
Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
    Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:6

    Topics: Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peptides, Cyclic; Radiopharmaceuticals; Receptors, Somatostatin; Retreatment; Somatostatin; Stomach Neoplasms; Yttrium Radioisotopes

2012
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.
    European journal of nuclear medicine and molecular imaging, 2013, Volume: 40, Issue:8

    Topics: Aged; Female; Humans; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Somatostatin; Stomach Neoplasms; Treatment Outcome; Yttrium Radioisotopes

2013
Long-term results of PRRT in advanced bronchopulmonary carcinoid.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:3

    Topics: Aged; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cohort Studies; Creatinine; Data Collection; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Treatment Outcome

2016
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 58

    Topics: Adult; Disease-Free Survival; Female; Follow-Up Studies; Gallium Radioisotopes; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Receptors, Somatostatin; Registries; Remission Induction; Time Factors; Treatment Outcome

2016